{Reference Type}: Journal Article
{Title}: Genetic variants in the TNF pathway impact TNFi response in a mixed population with rheumatoid arthritis.
{Author}: Augusto Silva Dos Santos Rodrigues P;Lima de Oliveira A;Mattos Brandão K;de Sá Garcia Landeiro L;Cardoso Calmon L;Victor Andrade Cruz J;Dos Anjos Silva M;Flávia Silva Rocha A;Silva Carvalho de Souza D;Tupiná Alcântara de Moreira A;de Oliveira Santos J;Miranda Barbosa Dos Santos T;Pimentel Pinheiro G;Augusto Souza da Cruz Filho Á;Alexandrina Viana de Figueiredo C;de Moura Santos P;Dos Santos Costa R;
{Journal}: Gene
{Volume}: 928
{Issue}: 0
{Year}: 2024 Nov 30
{Factor}: 3.913
{DOI}: 10.1016/j.gene.2024.148804
{Abstract}: Rheumatoid arthritis (RA) is a multifactorial autoimmune inflammatory disease that mainly affects the joints, on reducing functional capacity and impacting quality of life. Cytokines such as tumor necrosis factor (TNF) and interleukin 6 (IL-6) are crucial in the pathogenesis and treatment of this disease. Some patients using TNF inhibitors (TNFi) do not respond or lose their response to these medications. Clinical, sociodemographic, and genetic data were used to evaluate the associations of single nucleotide polymorphisms (SNP) in TNF, TNFRSF1A, and TNFRSF1B genes with the diagnosis of RA, standardized score results, laboratory tests, and response to TNFi. In one subsample, TNF and IL-6 serum levels cytokines were performed. A total of 654 subjects (360 healthy controls and 294 diagnosed with RA) were included in the analysis. Higher levels of TNF have been found in individuals diagnosed with RA. IL-6 levels were higher in individuals who did not respond to TNFi treatment, while responders had levels comparable to those without the disease. No associations were found between the SNPs studied and the diagnosis of RA; however, rs767455-C seems to play a role in the response to golimumab treatment, being related to better therapeutic response and lower mean serum leukocyte levels. In addition, rs1061622-G was associated with poorer functional capacity and rs1800629-A was associated with higher leukocyte values and serum transaminase levels. The rs1061622-G and rs767455-C may play a role in the response to TNFi treatment, especially for patients using golimumab, although they do not seem to be associated with the diagnosis of RA. Polymosphisms in the TNF pathway may impact baseline levels of immune cells and markers of renal and hepatic function in RA patients. Our results highlight the importance of evaluating the impact of these polymorphisms on TNFi response and safety, particularly in larger-scale studies.